These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21474823)

  • 1. Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
    Blaha MJ; Rivera JJ; Budoff MJ; Blankstein R; Agatston A; O'Leary DH; Cushman M; Lakoski S; Criqui MH; Szklo M; Blumenthal RS; Nasir K
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1430-8. PubMed ID: 21474823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
    Targher G
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1251-2. PubMed ID: 21593456
    [No Abstract]   [Full Text] [Related]  

  • 3. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.
    Blaha MJ; Budoff MJ; DeFilippis AP; Blankstein R; Rivera JJ; Agatston A; O'Leary DH; Lima J; Blumenthal RS; Nasir K
    Lancet; 2011 Aug; 378(9792):684-92. PubMed ID: 21856482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.
    Glynn RJ; MacFadyen JG; Ridker PM
    Clin Chem; 2009 Feb; 55(2):305-12. PubMed ID: 19095726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis.
    Mann DM; Shimbo D; Cushman M; Lakoski S; Greenland P; Blumenthal RS; Michos ED; Lloyd-Jones DM; Muntner P
    Clin Cardiol; 2013 Jan; 36(1):15-20. PubMed ID: 22886783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Obesity Phenotypes, Gender Effects, and Subclinical Atherosclerosis in African Americans: The Jackson Heart Study.
    Lin A; Lacy ME; Eaton C; Correa A; Wu WC
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2431-2438. PubMed ID: 27856456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein lowering with rosuvastatin in the METEOR study.
    Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
    J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is hsCRP Back on Board? Implications from the JUPITER Trial.
    Koenig W
    Clin Chem; 2009 Feb; 55(2):216-8. PubMed ID: 19074517
    [No Abstract]   [Full Text] [Related]  

  • 17. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jupiter to Earth: CRP promotes atherothrombosis.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
    [No Abstract]   [Full Text] [Related]  

  • 19. METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis.
    Haddad RM; Ballantyne CM
    Phys Sportsmed; 2010 Jun; 38(2):180-2. PubMed ID: 20631478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.